Ovarian cancer (OC) is the most lethal gynecological malignancy, often referred to as the 'silent killer.' Accounting for 150,000 deaths and nearly 300,000 new cases globally each year, this devastating disease is typically diagnosed too late, with over 80% of cases detected at advanced stages. At this point, the 5-year survival rate drops to just 20%. However, early detection could significantly increase survival rates to 93%.   

Currently, the standard biomarker, CA125, is unreliable for early-stage detection, highlighting the urgent need for better diagnostic tools. At Farname-Diagnosis, we are committed to providing valuable insights into ovarian cancer and working towards solutions that can help in the early detection of this silent threat.